U.S., April 19 -- ClinicalTrials.gov registry received information related to the study (NCT06934382) titled 'Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma' on April 11.
Brief Summary: This will be a Phase 1, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with R/R T-ALL or T-LLy. BEAM-201 is an allogeneic anti-CD7 CART therapy.
Study Start Date: May 01
Study Type: INTERVENTIONAL
Condition:
T-Cell Acute Lymphoblastic Leukemia/Lymphoma
Intervention:
BIOLOGICAL: Allogeneic anti-CD7 CAR-T cells (BEAM-201)
The investigational agent in this protocol is allogeneic anti-CD7 CART cells (BEAM-201). BEAM-201 is comprised of allogeneic anti-CD7 CAR-T cells edited by 4 g...